ID
17655
Beschreibung
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Stichworte
Versionen (2)
- 01.08.16 01.08.16 -
- 27.09.16 27.09.16 -
Hochgeladen am
27. September 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Beschreibung
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Beschreibung
Record all topical creams, gels, oral or IV medications, and/or other interventions used to prevent and treat skin, hair and nail reactions (includes rash, skin fissures, nail and hair changes, etc) due to study drug administration. Moisturizers and sunscreens used to prevent and treat skin reactions should be recorded on the Moisturizers and Sunscreens CRF page.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [1,2]
- C0221743 (Skin reaction)
- SNOMED
- 251348006
- UMLS CUI [2,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [2,2]
- C0018500 (Hair Diseases)
- SNOMED
- 279425004
- UMLS CUI [3,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [3,2]
- C0234909 (Nail changes)
- SNOMED
- 416596008
Beschreibung
Indication Prophylaxis
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C3146298 (Indication)
- UMLS CUI [1,2]
- C0199176 (Prophylactic treatment)
- SNOMED
- 360271000
Beschreibung
Drug Administration Route
Datentyp
integer
Alias
- UMLS CUI [1]
- C0013153 (Drug Administration Routes)
- SNOMED
- 410675002
- LOINC
- LP40261-7
Beschreibung
Drug Administration Route
Datentyp
text
Alias
- UMLS CUI [1]
- C0013153 (Drug Administration Routes)
- SNOMED
- 410675002
- LOINC
- LP40261-7
Beschreibung
Specific Indication should be reported on the Adverse Event (Including Baseline Signs/Symptoms) CRF page, unless the intervention was given as a prophylaxis.
Datentyp
integer
Alias
- UMLS CUI [1]
- C3146298 (Indication)
Beschreibung
Indication
Datentyp
text
Alias
- UMLS CUI [1]
- C3146298 (Indication)
Beschreibung
Date Started
Datentyp
date
Alias
- UMLS CUI [1]
- C3173309 (Date treatment or therapy started)
- LOINC
- LP262646-5
Beschreibung
Date Stopped
Datentyp
date
Alias
- UMLS CUI [1]
- C1531784 (Date treatment stopped)
- SNOMED
- 413947000
Beschreibung
Date Stopped
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1531784 (Date treatment stopped)
- SNOMED
- 413947000
Ähnliche Modelle
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0199176 (UMLS CUI [1,2])
Keine Kommentare